Ocugen, Inc. · NASDAQ:OCGN
Ocugen — Q2 2025 Earnings Presentation
18 slides from Ocugen's earnings presentation, Aug 1, 2025
Slide 1: 2Q 2025 Business Update
Courageous Innovation Dedicated to Bringing Game - Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally 2Q 2025 Business Update August 1, 2025
Slide 2: Forward-looking statements
2 This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 , including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the precl ini cal and clinical develop
Slide 3: Potential for Three Biologics License Applications in the Next Three Years
Potential for Three Biologics License Applications (BLAs) in the Next Three Years Target BLA/MAA Submission U.S./EU Prevalence Status Product Candidate 2026 300,000 Phase 3 in Progress (Largest Orphan Gene Therapy Clinical Trial) – on Target to File BLA in 2026 Collaboration with Molly Burke to Rais
Slide 4: OCU400 First-in-Class Novel Modifier Gene Therapy for RP
OCU400 First - in - Class Novel Modifier Gene Therapy for RP Unmet Need ~300,000 people in the U.S./EU and 1.6 million globally suffer from RP, which affects > 100 genes One approved product (Luxturna ® ), a gene therapy, which can address only one gene ( RPE65 ) 4 2,000 298,000 OCU400 Market Potent
Slide 5: OCU410ST First-in-Class Novel Modifier Gene Therapy Product for Stargardt Disease
OCU410ST First - in - Class Novel Modifier Gene Therapy Product for Stargardt Disease 5 100,000 OCU410ST Market Potential OCU410ST Pricing for current gene therapies ranges between $1 - 4M/patient Received ODD & OMPD for ABCA4 - associated Retinopathies 2 https://www.rxcinternational.com/monthly - g
Slide 6: Stargardt Disease (GARDian3) Clinical Trial
Stargardt Disease (GARDian3) Clinical Trial 6 • The GARDian3 clinical trial for ABCA4 - related retinopathies including Stargardt disease builds upon encouraging results and positive data from the Phase 1 GARDian trial, which demonstrated 48% slower lesion growth at 12 - month follow - up in evaluab
Slide 7: OCU410 First-in-Class Novel Modifier Gene Therapy for GA
OCU410 First - in - Class Novel Modifier Gene Therapy for GA 7 • 2 approved products for GA: FY ‘24 sales SYFOVRE ® (Apellis): $611M (Full Year) IZERVAY (Astellas): $107M • OCU410 has potential to treat 2 - 3 million patients in U.S. and EU • Pricing for current gene therapies ranges between $1 - 4M
Slide 8: GA Lesion Growth after single sub-retinal injection – All Subjects (Phase 1)
GA Lesion Growth after single sub - retinal injection – All Subjects (Phase 1) • 23% slower GA lesion growth in treated eyes versus fellow eyes after single injection Data points at 12M (N=6) GA growth rates per Natural History Studies obtained from Proxima A study 12M 0.0 0.5 1.0 1.5 2.0 M e a n c
Slide 9: Preservation of Visual Function (LLVA) in OCU410 Treated vs Untreated Eyes (Phase 1)
Preservation of Visual Function (LLVA) in OCU410 Treated vs Untreated Eyes (Phase 1) Stabilization : ± 4 letters from Baseline; Improvement: ≥5 Letters from Baseline Data points at 3M (N=8), 6M (N=7), 12M (N=6) BL 3M 6M 12M -25 -20 -15 -10 -5 0 5 10 M e a n c h a n g e i n L L V A ( E T D R S ) f r
Slide 10: GA Lesion Growth after single sub-retinal injection: Phase 2 – Preliminary Data
GA Lesion Growth after single sub - retinal injection: Phase 2 – Preliminary Data 27% slower GA lesion growth in evaluable treated eyes versus fellow eyes after single injection 6M 0.0 0.5 1.0 1.5 M e a n C h a n g e f r o m B a s e l i n e ( ± S E M ) i n G A l e s i o n ( m m 2 ) Control Eyes Trea
Slide 11: OCU410 Treatment shows reduction in GA Lesions at 6M (Phase 2)
11 13 12% 27% 0 5 10 15 20 25 30 PM (6M) PEOM (6M) OCU410(6M) Lesion Growth Reduction vs pooled sham or control (untreated) OCU410 Treatment shows reduction in GA Lesions at 6M (Phase 2 — Preliminary Data) Based on reading from the Chart for OAKS and DERBY study results which used Sham controls in l
Slide 12: OCU410 Treatment Preserves Retinal Tissue in GA Lesions (Phase 2)
12 0.14 0.12 0.31 0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 PM (6M) PEOM (6M) OCU410(6M) Difference in Mean GA lesion Size between Treated and Untreated Eyes (mm 2 ) OCU410 Treatment Preserves Retinal Tissue in GA Lesions (Phase 2 – Preliminary Data) Based on reading from the Chart for OAKS and DERBY study
Slide 13: Binding Term Sheet Signed for First Regional Partnership for OCU400 and NeoCart Spin-off into OrthoCellix
Binding Term Sheet Signed for our First Regional Partnership for OCU400 and Announced the spin - off of NeoCart into OrthoCellix 13 OCU400 • Company signed a term sheet to negotiate and enter into a licensing agreement with a well - established leader in the pharmaceutical and healthcare sector in K
Slide 14: New Appointments to Board of Directors, Retina SAB & Executive Team
New Appointments to Board of Directors, Retina SAB & Executive Team 14
Slide 15: Financial Update
Financial Update ocugen.
Slide 16: Financial Update: Three months ended June 30, 2025
Financial Update Three months ended June 30, 2025 Statement of Operations 2024 2025 $8.9 $8.4 Research and development expense $7.7 $6.8 General and administrative expense $0.2 $(1.1) Interest (expense) income, net $( 15.3) $(14.7) Net loss $(0.06) $(0.05) Net loss per share of common stock — basic
Slide 17: Questions & Answers
Questions & Answers ocugen.
Slide 18: Ocugen Vision
18 Ocugen Vision Fully integrated, patient - centric b iotech company focused on vaccines in support of public health and gene and cell therapies targeting unmet medical needs through Courageous Innovation